Xeris Biopharma price target raised to $6 from $5.50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Xeris Biopharma to $6 from $5.50 and keeps a Buy rating on the shares post the Q4 results. The company reported its sixth straight revenue beat, the analyst tells investors in a research note. The fir says the weakness in the stock post results is unmerited.